Dapagliflozin: all 489 studies that test it

Page 2 of 5. Open to participants first (118), then studies with results posted, then the rest; newest registration first within each.

• SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AFRecruitingNCT05852704Phase 3
• Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)RecruitingNCT05848102Phase 4
• Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV ProcedureRecruitingNCT05816733Phase 4
• Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart FailureRecruitingNCT05776043Phase 3
• DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial InfarctionRecruitingNCT05764057Phase 3
• Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery DiseaseRecruitingNCT05762952Phase 1
• Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD StudyRecruitingNCT05713851Phase 2/3
• DApagliflozin Cardiovascular Effects on Patients at End-stage REnal DiseaseRecruitingNCT05685394Phase 4
• Dapagliflozin Effect in Cognitive Impairment in Stroke TrialRecruitingNCT05565976Phase 2/3
• Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone PatientsNot yet recruitingNCT05443932Phase 4
• Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKDRecruitingNCT05359263Phase 2
• SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 DiabetesRecruitingNCT05345327Phase 3
• Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 DiabetesRecruitingNCT05194592Phase 4
• Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)RecruitingNCT05174052Phase 3
• Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)RecruitingNCT04707261Phase 4
• Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.RecruitingNCT04662723Phase 4
• DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular RiskRecruitingNCT04258371Phase 2
• Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)RecruitingNCT02969798Not applicable
• A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCKCompletedNCT06269484Phase 2Results posted
• Anti-Diabetic Medications to Fight PD and LBDCompletedNCT06263673Phase 4Results posted
• Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis PatientsCompletedNCT05748925Phase 4Results posted
• Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)TerminatedNCT05516498Phase 2Results posted
• Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 DiabetesTerminatedNCT05139914Phase 4Results posted
• Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant RecipientsCompletedNCT04965935Phase 3Results posted
• Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and FulvestrantTerminatedNCT04899349Phase 2Results posted
• The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary StudyCompletedNCT04818034Phase 2Results posted
• Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial FibrillationCompletedNCT04792190Phase 4Results posted
• Dapagliflozin (DAPA) Effects in HFpEFCompletedNCT04730947Phase 2Results posted
• Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.CompletedNCT04564742Phase 3Results posted
• Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) InhibitionCompletedNCT04542291Phase 1Results posted
• To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus PatientsCompletedNCT04445714Phase 4Results posted
• SGLT2 Inhibition in Older Obese Adults With Pre-diabetesCompletedNCT04401904Phase 1/2Results posted
• Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)CompletedNCT04363697Phase 4Results posted
• Dapagliflozin in Respiratory Failure in Patients With COVID-19CompletedNCT04350593Phase 3Results posted
• Efficacy and Safety of Dapagliflozin in Acute Heart FailureCompletedNCT04298229Phase 3Results posted
• Dapagliflozin at Discharge on Hospital Heart Failure ReadmissionCompletedNCT04249778Phase 4Results posted
• Effectiveness of Dapagliflozin for Weight LossCompletedNCT03968224Phase 2/3Results posted
• DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection FractionCompletedNCT03877237Phase 3Results posted
• DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection FractionCompletedNCT03877224Phase 3Results posted
• Dapagliflozin In Alzheimer's DiseaseCompletedNCT03801642Phase 1/2Results posted
• Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2CompletedNCT03782259Phase 4Results posted
• Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes MellitusTerminatedNCT03660683Phase 4Results posted
• Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.CompletedNCT03619213Phase 3Results posted
• A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes PatientsCompletedNCT03387683Phase 4Results posted
• Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.CompletedNCT03338855Phase 4Results posted
• Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in GlucosuriaCompletedNCT03331289Phase 4Results posted
• A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UACompletedNCT03316131Phase 2Results posted
• Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years OldCompletedNCT03199053Phase 3Results posted
• Effects of Dapagliflozin in Non-diabetic Patients With ProteinuriaCompletedNCT03190694Phase 2Results posted
• Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?CompletedNCT03180489Phase 2Results posted
• The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.TerminatedNCT03152084Phase 4Results posted
• Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)CompletedNCT03074630Phase 4Results posted
• A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney DiseaseCompletedNCT03036150Phase 3Results posted
• Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart FailureCompletedNCT03036124Phase 3Results posted
• Dapagliflozin in PRESERVED Ejection Fraction Heart FailureCompletedNCT03030235Phase 4Results posted
• Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and PrehypertensionCompletedNCT03006471Phase 4Results posted
• Paradoxical Stimulation of Hepatic Glucose Production With DapagliflozinCompletedNCT02984644Phase 3Results posted
• Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism SubjectsCompletedNCT02981966Phase 4Results posted
• Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DMCompletedNCT02981069Phase 4Results posted
• Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)CompletedNCT02973477Phase 4Results posted
• An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 DiabetesCompletedNCT02962492Not applicableResults posted
• Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With HyperfiltrationCompletedNCT02911792Phase 4Results posted
• Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 DiabetesCompletedNCT02796170Phase 4Results posted
• Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 DiabetesCompletedNCT02777073Not applicableResults posted
• Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 YearsCompletedNCT02725593Phase 3Results posted
• An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed ConditionsCompletedNCT02722239Phase 1Results posted
• Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With PrediabetesCompletedNCT02700334Phase 4Results posted
• Renoprotective Effects of Dapagliflozin in Type 2 DiabetesCompletedNCT02682563Phase 4Results posted
• A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 DiabetesCompletedNCT02681094Phase 3Results posted
• Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart FailureCompletedNCT02653482Phase 4Results posted
• EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)CompletedNCT02635386Phase 3Results posted
• ESR-15-11293 - Saxa/Dapa, Safety and Efficacy StudyCompletedNCT02613897Not applicableResults posted
• Effect of Dapagliflozin on Inflammation and Endothelial FunctionTerminatedNCT02608905Phase 4Results posted
• SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2CompletedNCT02592421Phase 3Results posted
• The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DMCompletedNCT02582840Phase 1Results posted
• The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DMCompletedNCT02582814Phase 3Results posted
• Foxiga Korea Local Phase 4 StudyCompletedNCT02564926Phase 4Results posted
• Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With ForxigaCompletedNCT02561130Phase 4Results posted
• A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKDCompletedNCT02547935Phase 2/3Results posted
• Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?TerminatedNCT02520518Phase 2Results posted
• Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 DiabetesCompletedNCT02518945Phase 3Results posted
• Vildagliptin Versus Dapagliflozin on GlucagonCompletedNCT02475070Phase 4Results posted
• Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With SulphonylureaCompletedNCT02471404Phase 4Results posted
• Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 DiabetesCompletedNCT02460978Phase 3Results posted
• An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of DapagliflozinCompletedNCT02433678Phase 4Results posted
• Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes MellitusCompletedNCT02426541Phase 4Results posted
• A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin AloneCompletedNCT02419612Phase 3Results posted
• A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 DiabetesCompletedNCT02413398Phase 3Results posted
• Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?CompletedNCT02371187Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy AloneCompletedNCT02284893Phase 3Results posted
• A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic PatientsCompletedNCT02279407Phase 2Results posted
• Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 DiabetesCompletedNCT02268214Phase 3Results posted
• Dapagliflozin Effects on Epicardial FatCompletedNCT02235298Phase 4Results posted
• Bioequivalence Study Coadministered to Healthy Subjects in the Fasted StateCompletedNCT02223065Phase 1Results posted
• Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.CompletedNCT02157298Phase 4Results posted
• Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin SecretionCompletedNCT02113241Phase 2/3Results posted
• Phase III Insulin Add-On Asia Regional Program - STCompletedNCT02096705Phase 3Results posted
• Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular EventsCompletedNCT01730534Phase 3Results posted
• Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy ParticipantsCompletedNCT01662999Phase 1Results posted
• Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 DiabetesCompletedNCT01646320Phase 3Results posted

← Dapagliflozin overview